In a recent symposium held in line with the 6th International Osteoporosis Foundation meeting in Singapore, Professor Serge Ferrari outlined the results of the FREEDOM trial and its extension study. According to these studies, continuous long-term use of denosumab, a fully human monoclonal antibody that inhibits RANKL, resulted in sustained reduction of bone turnover, continued gains in bone density, and continued low yearly fracture incidence in osteoporosis.
At a recent satellite symposium convened during the 11th Asian & Oceanian Epilepsy Congress (AOEC) in Hong Kong, experts on convulsive epilepsy discussed the dilemmas and challenges currently encountered in the diagnosis and subsequent management of generalized tonic-clonic (GTC) seizures. The symposium was chaired by Dr Ada Yung (Associate Consultant, Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong), and it focused in particular on perampanel, the first and only approved non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonist. Perampanel is approved for the management of patients experiencing partial-onset seizures, with or without secondarily generalized seizures, in seven countries across Asia and for primary GTC seizures in four Asian countries, with more approvals expected later this year.
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, was associated with a reduced rate of disability progression in individuals with primary progressive multiple sclerosis (MS), based on findings of the phase III ORATORIO* trial.
Chronic venous disease (CVD) places a significant burden on health care. At a recent Servier- sponsored symposium during the 17th Congress of the Asian Society for Vascular Surgery (ASVS) 2016 held in Singapore, Assistant Professor Benjamin Chua of the Vascular and Interventional Centre, Singapore, Professor Andrew Nicolaides of Imperial College, London, UK, and Professor Armando Mansilha of CUF Porto Hospital, Porto, Portugal, discussed the prevalence of CVD and the use of venoactive drugs to relieve symptoms of the disease. In particular, the efficacy of micronized purified flavonoid fraction (MPFF, Daflon®, Servier) in treating symptoms at all stages of CVD was highlighted.
On 15 October 2016, Menarini hosted a lunch symposium entitled Invigorating Lives at the Sheraton Towers, Singapore to discuss approaches to the management of urticaria, atopic dermatitis, allergic rhinitis and asthma. Experts Marcus Maurer (Germany), Mark Tang (Singapore) and David Chin (Singapore) were invited to share their insights and experiences on these topics, and to discuss the current landscape and advances in these fields.
AMARYL– Glimepiride 1 mg, 2 mg and 3 mg tab – Sanofi-Aventis
ACE inhibitor-based combination therapy important for improving BP control in the Asia Pacific region
Hypertension is a leading cause of mortality globally and is of particular concern in the Asia Pacific region where there are more deaths due to poor blood pressure (BP) control than in any other region in the world. At a recent Servier-sponsored satellite symposium held during the ASEAN Federation of Cardiology Congress in Yangon, Myanmar, Professor Abdul Rashid, An Nur Specialist Hospital, Selangor, Malaysia, discussed the challenges associated with managing hypertension in the region. In addition, Professor Martin Strauss, North York General Hospital, Toronto, Canada and Professor Alistair Hall, Leeds General Infirmary, UK, discussed the different effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) on cardiovascular (CV) outcomes, highlighting the additional protection against myocardial infarction (MI) offered by ACE inhibitors such as perindopril.
Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.
Sorafenib appears to be well-tolerated in patients with hepatocellular carcinoma (HCC), with the subgroup of Child-Pugh B patients having a shorter treatment duration and higher serious adverse event (SAE) incidence, according to the results of a subgroup analysis of GIDEON*.
Dengvaxia, a recombinant, live-attenuated dengue vaccine, has the potential to bring down the number of hospitalizations by 13 to 25 percent and be cost-effective in areas of moderate-to-high dengue endemicity, according to a model comparison study.